Robert G Micheletti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8386505/publications.pdf

Version: 2024-02-01

118 papers 3,003 citations

28 h-index

186265

189892 50 g-index

122 all docs 122 docs citations

times ranked

122

2994 citing authors

#	Article	IF	CITATIONS
1	North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Journal of the American Academy of Dermatology, 2019, 81, 76-90.	1.2	218
2	North American clinical management guidelines for hidradenitis suppurativa: AÂpublication from the United States and Canadian Hidradenitis Suppurativa Foundations. Journal of the American Academy of Dermatology, 2019, 81, 91-101.	1.2	206
3	Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. Journal of the American Academy of Dermatology, 2020, 82, 366-376.	1.2	165
4	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 38-69.	3.8	134
5	Prevention and management of glucocorticoid-induced side effects: A comprehensive review. Journal of the American Academy of Dermatology, 2017, 76, 1-9.	1.2	126
6	Neutrophilic dermatoses. Journal of the American Academy of Dermatology, 2018, 79, 987-1006.	1.2	122
7	Prevention and management of glucocorticoid-induced side effects: A comprehensive review. Journal of the American Academy of Dermatology, 2017, 76, 201-207.	1.2	115
8	The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum. JAMA Dermatology, 2018, 154, 409.	4.1	105
9	Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the UnitedÂStates. Journal of Investigative Dermatology, 2018, 138, 2315-2321.	0.7	94
10	Mönckeberg Sclerosis Revisited: A Clarification of the Histologic Definition of Mönckeberg Sclerosis. Archives of Pathology and Laboratory Medicine, 2008, 132, 43-47.	2.5	90
11	Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. Journal of the American Academy of Dermatology, 2022, 86, 1092-1101.	1.2	77
12	Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center. Journal of the American Academy of Dermatology, 2018, 78, 303-309.e4.	1.2	76
13	Neutrophilic dermatoses. Journal of the American Academy of Dermatology, 2018, 79, 1009-1022.	1.2	73
14	Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis—ABCD-10. JAMA Dermatology, 2019, 155, 448.	4.1	69
15	Prevention and management of glucocorticoid-induced side effects: A comprehensive review. Journal of the American Academy of Dermatology, 2017, 76, 11-16.	1.2	68
16	Small Vessel Vasculitis of the Skin. Rheumatic Disease Clinics of North America, 2015, 41, 21-32.	1.9	58
17	Prevention and management of glucocorticoid-induced side effects: A comprehensive review. Journal of the American Academy of Dermatology, 2017, 76, 191-198.	1.2	52
18	High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa. Journal of the American Academy of Dermatology, 2020, 82, 1094-1101.	1.2	51

#	Article	IF	CITATIONS
19	A Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic Criteria. JAMA Dermatology, 2020, 156, 270.	4.1	49
20	Atherosclerotic oxalosis in coronary arteries. Cardiovascular Pathology, 2008, 17, 117-123.	1.6	42
21	SJS/TEN 2019: From science to translation. Journal of Dermatological Science, 2020, 98, 2-12.	1.9	41
22	Primary Cutaneous Cryptococcus in a Patient With Multiple Sclerosis Treated With Fingolimod. JAMA Neurology, 2016, 73, 355.	9.0	38
23	Coronary atherosclerotic lesions in human immunodeficiency virus–infected patients: a histopathologic study. Cardiovascular Pathology, 2009, 18, 28-36.	1.6	35
24	Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. Journal of the American Academy of Dermatology, 2020, 82, 1553-1567.	1.2	35
25	Calcification of the internal elastic lamina of coronary arteries. Modern Pathology, 2008, 21, 1019-1028.	5 . 5	34
26	Hidradenitis Suppurativa: Current Views on Epidemiology, Pathogenesis, and Pathophysiology. Seminars in Cutaneous Medicine and Surgery, 2014, 33, S48-S50.	1.6	32
27	Diffuse HIV-associated seborrheic dermatitis $\hat{a} \in \hat{a}$ a case series. International Journal of STD and AIDS, 2016, 27, 1342-1345.	1.1	31
28	A small n sequential multiple assignment randomized trial design for use in rare disease research. Contemporary Clinical Trials, 2016, 46, 48-51.	1.8	31
29	Cutaneous Manifestations of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis and Rheumatology, 2020, 72, 1741-1747.	5.6	31
30	Clinical Characteristics, Disease Course, and Outcomes of Patients With Acute Generalized Exanthematous Pustulosis in the US. JAMA Dermatology, 2022, 158, 176.	4.1	31
31	Atypical manifestations of graft-versus-host disease. Journal of the American Academy of Dermatology, 2015, 72, 690-695.	1.2	30
32	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines. JAMA Dermatology, 2017, 153, 587.	4.1	30
33	Natural History, Presentation, and Diagnosis of Hidradenitis Suppurativa. Seminars in Cutaneous Medicine and Surgery, 2014, 33, S51-S53.	1.6	28
34	Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. Journal of the American Academy of Dermatology, 2020, 83, 1150-1159.	1.2	27
35	Use of teledermatology by dermatology hospitalists is effective in the diagnosis and management of inpatient disease. Journal of the American Academy of Dermatology, 2021, 84, 1547-1553.	1.2	27
36	FLT3Inhibitor–Associated Neutrophilic Dermatoses. JAMA Dermatology, 2016, 152, 480.	4.1	25

3

#	Article	IF	CITATIONS
37	Developing classification criteria for skinâ€predominant dermatomyositis: the Delphi process. British Journal of Dermatology, 2020, 182, 410-417.	1.5	25
38	Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis. Clinics in Dermatology, 2020, 38, 607-612.	1.6	22
39	How Dermatologists Can Learn and Contribute at the Leading Edge of the COVID-19 Global Pandemic. JAMA Dermatology, 2020, 156, 733.	4.1	22
40	Supportive care in the acute phase of Stevens–Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphiâ€based consensus. British Journal of Dermatology, 2021, 185, 616-626.	1.5	22
41	Cutaneous vasculitis in rheumatologic disease: Current concepts of skin and systemic manifestations. Clinics in Dermatology, 2018, 36, 561-566.	1.6	20
42	Management of cutaneous vasculitis. Presse Medicale, 2020, 49, 104033.	1.9	20
43	Bedside diagnostics in dermatology. Journal of the American Academy of Dermatology, 2017, 77, 197-218.	1.2	19
44	Long-term Physical and Psychological Outcomes of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. JAMA Dermatology, 2021, 157, 712.	4.1	19
45	A survey-based study of diagnostic and treatment concordance in standardized cases of cellulitis and pseudocellulitis via teledermatology. Journal of the American Academy of Dermatology, 2020, 82, 1221-1223.	1.2	18
46	Retrospective review of drugâ€induced Stevensâ€johnson syndrome and toxic epidermal necrolysis cases at a pediatric tertiary care institution. Pediatric Dermatology, 2020, 37, 461-466.	0.9	18
47	Inpatient dermatology consultation in patients with hematologic malignancies. Journal of the American Academy of Dermatology, 2016, 75, 835-836.	1.2	17
48	Bedside diagnostics in dermatology. Journal of the American Academy of Dermatology, 2017, 77, 221-230.	1.2	17
49	Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. European Journal of Clinical Pharmacology, 2019, 75, 1135-1141.	1.9	16
50	Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: A retrospective chart review. Journal of the American Academy of Dermatology, 2020, 82, 507-510.	1.2	15
51	Creation of a Registry to Address Knowledge Gaps in Hidradenitis Suppurativa and Pregnancy. JAMA Dermatology, 2020, 156, 353.	4.1	14
52	Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone. Trials, 2020, 21, 362.	1.6	14
53	Neutrophilic Dermatoses: a Clinical Update. Current Dermatology Reports, 2022, 11, 89-102.	2.1	14
54	Tobacco smoking and hidradenitis suppurativa: associated disease and an important modifiable risk factor. British Journal of Dermatology, 2018, 178, 587-588.	1.5	13

#	Article	IF	CITATIONS
55	Pemetrexed-Induced Pseudocellulitis Reaction With Eosinophilic Infiltrate on Skin Biopsy. American Journal of Dermatopathology, 2017, 39, e1-e2.	0.6	12
56	<i>Stenotrophomonas maltophilia</i> : an emerging multidrug-resistant opportunistic pathogen in the immunocompromised host. BMJ Case Reports, 2017, 2017, bcr-2017-221053.	0.5	9
57	Robotic teledermatopathology from an African dermatology clinic. Journal of the American Academy of Dermatology, 2014, 70, 952-954.	1.2	8
58	The ABCD-10 Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysisâ€"Reply. JAMA Dermatology, 2019, 155, 1088.	4.1	8
59	An update on the diagnosis and treatment of hidradenitis suppurativa. Cutis, 2015, 96, 7-12.	0.3	8
60	Striking Follicular Eruption to Pegylated Liposomal Doxorubicin. American Journal of Dermatopathology, 2014, 36, 590-591.	0.6	7
61	Selective Use of Cyclosporine for Stevens-Johnson Syndrome/Toxic EpidermalÂNecrolysis May Exclude PatientsÂwith Poor Prognostic Factors. Journal of Investigative Dermatology, 2018, 138, 2068-2072.	0.7	7
62	A Crusted Rash in a Patient With AIDS. JAMA - Journal of the American Medical Association, 2015, 313, 298.	7.4	6
63	Pregnancy in Hidradenitis Suppurativaâ€"Patient Perspectives and Practice Gaps. JAMA Dermatology, 2021, 157, 227.	4.1	6
64	Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?. American Journal of Clinical Dermatology, 2021, 22, 139-147.	6.7	6
65	A Violaceous Plaque in an Immunosuppressed Patient. JAMA - Journal of the American Medical Association, 2012, 307, 2635.	7.4	5
66	Cryptococcal meningitis presenting with headache and a pustular eruption in a heart transplant patient. Transplant Infectious Disease, 2015, 17, 716-718.	1.7	5
67	Chronic idiopathic Sweet syndrome: A report of 2 cases. JAAD Case Reports, 2016, 2, 227-229.	0.8	5
68	Alopecia neoplastica. BMJ Case Reports, 2017, 2017, bcr-2017-220215.	0.5	5
69	Calcinosis Cutis in the Setting of Chronic Skin Graft-Versus-Host Disease. JAMA Dermatology, 2020, 156, 814.	4.1	5
70	Long-term sequelae from Stevens-Johnson syndrome/toxic epidermal necrolysis in a large retrospective cohort. Journal of the American Academy of Dermatology, 2021, 84, 784-786.	1.2	5
71	Ablative fractional laser resurfacing for treatment of sclerosis and contractures in chronic graft-versus-host disease: A pilot study. Journal of the American Academy of Dermatology, 2020, 82, 984-986.	1.2	4
72	Medical management of Stevens-Johnson syndrome/toxic epidermal necrolysis among North American dermatologists. Journal of the American Academy of Dermatology, 2021, , .	1.2	4

#	Article	IF	Citations
73	Introduction. Seminars in Cutaneous Medicine and Surgery, 2014, 33, S47-S47.	1.6	4
74	Robert Chesebrough and the Dermatologic Wonder of Petroleum Jelly. JAMA Dermatology, 2017, 153, 1157.	4.1	3
75	Introducing "lmages in Dermatology― JAMA Dermatology, 2018, 154, 1255.	4.1	3
76	Bullous dermatosis suspected in an 8-month-old child in Guinea-Bissau. Oxford Medical Case Reports, 2019, 2019, omz004.	0.4	3
77	Hidradenitis suppurativa encounters in a national electronic health record database notable for low dermatology utilization, infrequent biologic prescriptions, and frequent opiate prescriptions. Journal of the American Academy of Dermatology, 2020, 82, 1239-1241.	1.2	3
78	Low utility of radiologic imaging in evaluating cutaneous small-vessel vasculitis: A multi-institutional retrospective study. Journal of the American Academy of Dermatology, 2021, 84, 1197-1199.	1.2	3
79	Cutaneous Manifestations of COVID-19: Characteristics, Pathogenesis, and the Role of Dermatology in the Pandemic., 2021, 107, 209-215.		3
80	Medical management of hidradenitis suppurativa. Seminars in Cutaneous Medicine and Surgery, 2017, 36, 62-66.	1.6	3
81	An approach to the hospitalized patient with urticaria and fever. Dermatologic Therapy, 2011, 24, 187-195.	1.7	2
82	Distal Matrix Glomus Tumor Presenting as Longitudinal Erythronychia: A Pearl for Surgical Management. Dermatologic Surgery, 2012, 38, 133-134.	0.8	2
83	The importance of multidisciplinary healthcare for paraneoplastic pemphigus. Special Care in Dentistry, 2015, 35, 143-147.	0.8	2
84	Refractory Cutaneous Alternariosis Successfully Treated With Mohs Surgery and Full-Thickness Skin Grafting. Dermatologic Surgery, 2016, 42, 426-429.	0.8	2
85	A cross-sectional survey of voriconazole prescribers: Assessing current practice and knowledge of cutaneous side effects. Journal of the American Academy of Dermatology, 2017, 77, 769-770.	1.2	2
86	Joseph Goldbergerâ€"Public Health Champion and Investigator of Pellagra. JAMA Dermatology, 2017, 153, 1262.	4.1	2
87	Atypical retiform hemangioendothelioma arising in a patient with Milroy disease: a case report and review of the literature. Journal of Cutaneous Pathology, 2017, 44, 98-103.	1.3	2
88	The potential costâ€savings of tumour necrosis factor inhibitors for hidradenitis suppurativa. British Journal of Dermatology, 2019, 180, 988-989.	1.5	2
89	Corticosteroid use in chronic dermatologic disorders and osteoporosis. International Journal of Women's Dermatology, 2021, 7, 545-551.	2.0	2
90	Small Vessel Vasculitis of the Skin. , 2016, , 233-244.		2

#	Article	IF	CITATIONS
91	Update on calciphylaxis etiopathogenesis, diagnosis, and management. Cutis, 2018, 102, 395-400.	0.3	2
92	Cryptococcal cellulitis in a heart transplant recipient. JAAD Case Reports, 2016, 2, 403-405.	0.8	1
93	216 A new mortality prediction tool for Stevens-Johnson syndrome/toxic epidermal necrolysis. Journal of Investigative Dermatology, 2017, 137, S37.	0.7	1
94	The immune reconstitution of the skin following sexâ€mismatched allogeneic haematopoietic stem cell transplant: a prospective case series utilizing fluorescence <i>in situ</i> hybridization and immunohistochemistry. British Journal of Dermatology, 2018, 178, e55-e56.	1.5	1
95	Advances in cutaneous vasculitis research and clinical care. Annals of Translational Medicine, 2021, 9, 439-439.	1.7	1
96	Dermatologic support for oncology: Quantifying the consultative services received by hospitalized oncology patients. Journal of the American Academy of Dermatology, 2021, 85, 1367-1368.	1.2	1
97	Atypical Manifestations of Graft-Versus-Host Disease. , 2017, , 149-160.		1
98	Developing academic work and evidence to guide the practice of inpatient dermatology. Seminars in Cutaneous Medicine and Surgery, 2017, 36, 35-37.	1.6	1
99	Inter-rater reliability of cutaneous sarcoidosis assessment tools via remote photographic assessment. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, 34, 165-169.	0.2	1
100	An Enlarging Ulcer. American Journal of Medicine, 2011, 124, 915-917.	1.5	0
101	Disseminated coccidioidomycosis masquerading as a ruptured epidermal inclusion cyst in a healthy young adult from Philadelphia. International Journal of Dermatology, 2015, 54, e441-e442.	1.0	0
102	Optimizing "best available―medical options when practicing complex medical dermatology in resource-limited settings. Journal of the American Academy of Dermatology, 2016, 75, e171-e172.	1.2	0
103	Skin and Soft Tissue Infection in Transplant Recipients. , 2019, , 365-395.		0
104	Continued weekly adalimumab is an effective strategy in patients with hidradenitis suppurativa who show at least partial response to therapy at week 12. British Journal of Dermatology, 2019, 181, 886-887.	1.5	0
105	Numerous Pink-Purple Papules in a Middle-aged Man. JAMA Dermatology, 2019, 155, 1308.	4.1	0
106	Timing of mucocutaneous symptoms and medication discontinuation in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. Journal of the American Academy of Dermatology, 2019, 81, 1410-1412.	1.2	0
107	Reply to: "New validated diagnostic criteria for pyoderma gangrenosum― Journal of the American Academy of Dermatology, 2019, 80, e89.	1.2	0
108	Improving Outcomes for Patients With Epidermal Necrolysis. JAMA Dermatology, 2020, 156, 1289.	4.1	0

#	Article	IF	Citations
109	Reply. Arthritis and Rheumatology, 2021, 73, 1089-1089.	5.6	0
110	Authors' reply to the comment "High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa― Journal of the American Academy of Dermatology, 2021, 84, e203-e204.	1.2	0
111	What You Should Know About Hidradenitis Suppurativa: Information for Patients. Seminars in Cutaneous Medicine and Surgery, 2014, 33, S60-S61.	1.6	0
112	Cutaneous Manifestations of Sexually Transmitted Infections. , 2020, , 133-151.		0
113	Targeted Therapeutics: Biologics, Small Molecules. , 2022, , 182-190.		O
114	Telemedicine and dermatology hospital consultations during the COVIDâ€19 pandemic: a multiâ€centre observational study on resource utilization and conversion to inâ€person consultations during the COVIDâ€19 pandemic. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	0
115	Purple curvilinear papules on the back. Cutis, 2016, 98, E5-E7.	0.3	0
116	Enlarging red papulonodule on the chest. Cutis, 2018, 101, 78;117;118.	0.3	0
117	Erythematous plaques and nodules on the abdomen and groin. Cutis, 2019, 104, E24-E26.	0.3	0
118	Nutritional dermatoses in the hospitalized patient. Cutis, 2020, 105, 296;302-308;E1;E2;E3;E4;E5.	0.3	0